Renovorx announces new positive interim phase iii data demonstrating renovogem™ delays cancer progression by eight months in locally advanced pancreatic cancer

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today presented new positive data on progression-free survival (pfs) from the pivotal phase iii open label tiger-pac study of renovogem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (lapc). the interim data was featured as a late-breaking oral presentation at the 2023 esmo wor.
RNXT Ratings Summary
RNXT Quant Ranking